SPATA17 Inhibitors
SPATA17 inhibitors are chemical entities that indirectly attenuate the functional activity of SPATA17 through strategic intervention in specific signaling pathways. Rapamycin and Everolimus, for example, target the mTOR signaling pathway, which SPATA17 is thought to engage with. These inhibitors bind to FKBP-12 to form a complex that inhibits the mTORC1 complex, leading to a reduction in protein synthesis, cell growth, and proliferation, processes in which SPATA17 is potentially involved. Similarly, PP242, KU 0063794, Torin 1, and AZD2014, all mTOR inhibitors, attenuate both mTORC1 and mTORC2 complexes, resulting in a comprehensive diminishment of SPATA17 activity due to its association with these complexes. The suppression of mTOR signaling by these compounds is particularly impactful on SPATA17's function, as mTOR is a central regulator of cell growth and metabolism, which are integral to SPATA17's role.
The PI3K/AKT/mTOR pathway, upstream of SPATA17, is another target for inhibition by chemicals like LY 294002, Wortmannin, and PI-103, which specifically disrupt PI3K, leading to downstream effects on SPATA17 activity. These inhibitors reduce AKT phosphorylation, thereby indirectly impeding SPATA17 function by not allowing the full activation of the mTOR pathway. Additionally, Triciribine's specific inhibition of AKT activation further contributes to the reduction of SPATA17's activity, as AKT is a critical mediator of mTOR signaling. Furthermore, by obstructing MEK with PD 98059 and p38 MAP kinase with SB 203580, there is a compensatory reduction in mTOR signaling, which again, leads to a decrease in SPATA17 activity. These inhibitors, through their targeted actions on key components of signaling pathways, ensure a cumulative decrease in the functional activity of SPATA17, highlighting their essential roles in the indirect modulation of this protein's activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mammalian target of rapamycin (mTOR), a kinase that SPATA17 may function alongside within the mTOR signaling pathway. Inhibition of mTOR leads to a decrease in protein synthesis and cell proliferation, processes in which SPATA17 is potentially involved, resulting in diminished SPATA17 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a phosphatidylinositol 3-kinase (PI3K) inhibitor. Since PI3K is upstream in the AKT/mTOR pathway, the inhibition of PI3K leads to reduced AKT phosphorylation and subsequent mTOR activity. This indirect pathway inhibition results in the decreased function of SPATA17, which is thought to be associated with mTOR signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, similar in function to LY294002. It blocks the PI3K/AKT pathway leading to reduced activity of downstream proteins like mTOR. The lowered mTOR activity consequentially diminishes the functional activity of SPATA17. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits the activation of AKT, which is downstream of PI3K and upstream of mTOR in the signaling cascade. By preventing AKT activation, triciribine indirectly reduces SPATA17 activity by impeding the mTOR pathway's stimulation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a selective inhibitor of MEK, which is part of the ERK/MAPK pathway. While not directly connected to SPATA17, inhibition of the ERK/MAPK pathway could lead to a compensatory reduction in mTOR signaling due to crosstalk between pathways, thus decreasing SPATA17 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 selectively inhibits p38 MAP kinase. Inhibition of p38 can decrease mTOR activity due to interconnected signaling pathways, resulting in reduced SPATA17 activity due to its association with mTOR signaling. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $56.00 $169.00 | 8 | |
PP242 is an mTOR inhibitor that works by targeting both mTORC1 and mTORC2 complexes. With both complexes inhibited, the activity of proteins potentially interacting with mTOR, such as SPATA17, would be diminished. | ||||||
KU 0063794 | 938440-64-3 | sc-361219 | 10 mg | $209.00 | ||
KU 0063794 is a selective inhibitor of mTORC1 and mTORC2, similar to PP242. It results in decreased activity of mTOR and therefore would likely result in diminished SPATA17 activity. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $240.00 | 7 | |
Torin 1 is a potent and selective mTOR inhibitor affecting both mTORC1 and mTORC2. By inhibiting mTOR signaling, SPATA17 activity is indirectly diminished due to its potential role in mTOR pathways. | ||||||
AZD2014 | 1009298-59-2 | sc-364420 | 5 mg | $303.00 | 2 | |
AZD8055 is an ATP-competitive inhibitor of mTOR that inhibits both mTORC1 and mTORC2. This inhibition reduces the activity of downstream proteins which could include SPATA17, thereby diminishing its functional activity. | ||||||